Nov 18 (Reuters) - Canadian fund Brookfield (BN.TO), opens new tab plans to offer about 7 billion euros ($7.4 billion) for ...

Building upon a successful end-of-Phase 2 meeting, received FDA "Study May Proceed" letter for pivotal Phase 3 trial of amezalpat (TPST-1120) combination therapy to treat first-line HCCAnnounced agree ...

R&D expenses relating to fadraciclib were $0.9 million for the three months ended September 30 ... please refer to our most recent Annual Report on Form 10-K and other periodic and other filings we ...

Positive preliminary Phase 1b data in SEACRAFT-1 NRASm melanoma cohort bolsters conviction in ongoing SEACRAFT-2 registrational trial; Stage 1 ...

Top-line results from NCI/Alliance trial are expected to be presented ... please see the risk factors described in the company’s Annual Report on Form 10-K filed with the U.S. Securities and ...

Received tentative approval from the FDA for YUTREPIATM (treprostinil) inhalation powder for both pulmonary arterial hypertension (PAH) ...

Completed pre-BLA meeting with FDA with full alignment on content of BLA, including CMC module, and path for fourth quarter 2024 rolling BLA submission for PRGN-2012† ...

PRMT5-MTA Data at ENA 2024 Additionally, Schrödinger will present new preclinical data on its PRMT5-MTA inhibitor program at a poster session during the meeting on October 25 from 9:00 a.m. - 3: ...

Absent any valid election to the contrary, shareholders (both holding in certificated and uncertificated form (CREST members)) and persons ... we may refer to Shell's "Net Carbon Intensity" (NCI), ...